Antagonist activity at human CXCR2 expressed in HEK293 cells assessed as inhibition of CXCL8-induced intracellular Ca2+ release by fluorescence based calcium flux assay, IC50=40 nM
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay, IC50=30 nM
Antagonist activity at CXCR2 expressed in 7w CHO cells co-expressing human recombinant APP 751 assessed as inhibition of gamma-secretase-mediated amyloid beta42 production, IC50 = 0.5 μM.
測(cè)試在96孔微量滴定板中進(jìn)行,反應(yīng)混合物包含在20 mM Bis-Tris-丙烷中的1.0 μg/ml 膜蛋白,pH 8.0,與1.2 mM MgSO4,0.1 mM EDTA,25 mM NaCl,和0.03% CHAPS,以及以指示濃度加入的SB 225002 (10 mM 儲(chǔ)存于Me2SO),最終Me2SO濃度小于標(biāo)準(zhǔn)結(jié)合條件下的1%。通過(guò)加入0.25 nM 125I-IL-8 (2,200 Ci/mmol)啟動(dòng)結(jié)合。室溫下培養(yǎng)1小時(shí)后,板使用Tomtec 96孔采集器采集到1% 聚乙烯亞胺和0.5% BSA阻塞的玻璃纖維過(guò)濾器上,并用25 mM NaCl,10 mM Tris?HCl,1 mM MgSO4,0.5 mM EDTA,0.03% CHAPS,pH 7.4的溶液洗滌3次。將過(guò)濾器干燥,密封在包含10 ml Wallac 205 Betaplate 液體閃爍液的取樣袋中,并用Wallac 1205 Betaplate液體閃爍計(jì)數(shù)器計(jì)數(shù)。